P B Andersson
Overview
Explore the profile of P B Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tregoning S, Ballard R, Andersson P, Fehler H, van der Spuy Z
S Afr Med J
. 2000 Sep;
90(7):727-30.
PMID: 10985137
Objectives: To determine the prevalence of antibodies to Chlamydia trachomatis in women presenting with ectopic pregnancies to Groote Schuur Hospital. Methods: C. trachomatis antibody titres were measured using a modified...
2.
Suhy J, Rooney W, Goodkin D, Capizzano A, Soher B, Maudsley A, et al.
Mult Scler
. 2000 Jun;
6(3):148-55.
PMID: 10871825
Objective: To compare brain metabolite levels in patients with primary progressive (PP) and relapsing remitting (RR) MS and controls. Hypotheses: (1) creatine (Cr), a putative marker of gliosis, is elevated...
3.
Andersson P, Yuen E, Parko K, So Y
Neurology
. 2000 Jan;
54(1):40-4.
PMID: 10636123
Objective: Because diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) frequently is missed or delayed, we looked for electrodiagnostic features that raise suspicion of the disorder by making...
4.
Andersson P, Rando T
Curr Opin Pediatr
. 1999 Dec;
11(6):497-503.
PMID: 10590906
Neuromuscular disorders are common causes of weakness and hypotonia in the infantile period and in childhood. Accurate diagnosis of specific neuromuscular disorders depends first on identification of which aspect of...
5.
Waubant E, Goodkin D, Gee L, Bacchetti P, Sloan R, Stewart T, et al.
Neurology
. 1999 Oct;
53(7):1397-401.
PMID: 10534241
Objective: To 1) compare monthly serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-type 1 (TIMP-1) in patients with relapsing-remitting MS (RRMS) versus healthy controls and 2) determine...
6.
Katz J, Wolfe G, Andersson P, Saperstein D, ELLIOTT J, Nations S, et al.
Neurology
. 1999 Sep;
53(5):1071-6.
PMID: 10496268
Objective: To describe a sporadic motor neuron disorder that remains largely restricted to the upper limbs over time. Background: Progressive amyotrophy that is isolated to the upper limbs in an...
7.
Waubant E, Goodkin D, Sloan R, Andersson P
Neurology
. 1999 Sep;
53(4):874-6.
PMID: 10489060
We compared the number of new gadolinium-enhancing and T2-weighted lesions on six monthly MRI scans in eight patients with relapsing multiple sclerosis before and during treatment with weekly intramuscular interferon...
8.
Andersson P, Waubant E, Gee L, Goodkin D
Arch Neurol
. 1999 Sep;
56(9):1138-42.
PMID: 10488816
Objective: To use the new consensus definitions of primary progressive multiple sclerosis (PPMS) and progressive relapsing multiple sclerosis (PRMS) to report the demographic, clinical, and natural history characteristics of multiple...
9.
Waubant E, Sloan R, Andersson P, Goodkin D
Rev Neurol (Paris)
. 1999 Jun;
155 Suppl 2:S20-3.
PMID: 10367321
We compared the number of new gadolinium-enhancing (Gd+) and T2-weighted (T2W) lesions on 6-monthly MRI scans before and after initiating weekly intramuscular injections of interferon beta-1a (Avonex) 30 mcg. The...
10.
Andersson P, Goodkin D
Baillieres Clin Neurol
. 1999 Apr;
6(3):409-28.
PMID: 10101581
Multiple sclerosis remains incurable. The urgency of this problem, together with the need to test an ever increasing number of promising therapeutic agents emerging from animal studies, has renewed interest...